Health state utilities associated with hyperphagia: Data for use in cost-utility models

被引:0
|
作者
Howell, Timothy A. [1 ,8 ]
Matza, Louis S. [1 ]
Mallya, Usha G. [2 ]
Goldstone, Anthony P. [3 ,4 ]
Butsch, W. Scott [5 ]
Lazarus, Ethan [6 ,7 ]
机构
[1] Evidera, Patient Ctr Res, Bethesda, MD USA
[2] Rhythm Pharmaceut Inc, Value & Evidence, Boston, MA USA
[3] Imperial Coll London, Dept Brain Sci, Div Psychiat, PsychoNeuroEndocrinol Res Grp, London, England
[4] Hammersmith Hosp, Imperial Coll Healthcare NHS Trust, Dept Endocrinol, London, England
[5] Cleveland Clin, Bariatr & Metab Inst, Cleveland Hts, OH USA
[6] Clin Nutr Ctr, Greenwood Village, CO USA
[7] Univ Colorado, Dept Family Med, Sch Med, Aurora, CO USA
[8] Evidera, Patient Ctr Res, 7101 Wisconsin Ave,Ste 1400, Bethesda, MD 20814 USA
来源
OBESITY SCIENCE & PRACTICE | 2023年 / 9卷 / 04期
关键词
health state utilities; hyperphagia; obesity; time trade-off; QUALITY-OF-LIFE; PRADER-WILLI-SYNDROME; OBESITY; OVERWEIGHT; SIBLINGS;
D O I
10.1002/osp4.652
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveRare genetic diseases of obesity typically present with hyperphagia, a pathologic desire to consume food. Cost-utility models assessing the value of treatments for these rare diseases will require health state utilities representing hyperphagia. This study estimated utilities associated with various hyperphagia severity levels. MethodsFour health state vignettes were developed using published literature and clinician input to represent various severity levels of hyperphagia. Utilities were estimated for these health states in a time trade-off elicitation study in a UK general population sample. ResultsIn total, 215 participants completed interviews (39.5% male; mean age 39.1 years). Mean (SD) utilities were 0.98 (0.02) for no hyperphagia, 0.91 (0.10) for mild hyperphagia, 0.70 (0.30) for moderate hyperphagia, and 0.22 (0.59) for severe hyperphagia. Mean (SD) disutilities were -0.08 (0.10) for mild, -0.28 (0.30) for moderate, and -0.77 (0.58) for severe hyperphagia. ConclusionsThese data show increasing severity of hyperphagia is associated with decreased utility. Utilities associated with severe hyperphagia are similar to those of other health conditions severely impacting quality of life (QoL). These findings highlight that treatments addressing substantial QoL impacts of severe hyperphagia are needed. Utilities estimated here may be useful in cost-utility models of treatments for rare genetic diseases of obesity.
引用
收藏
页码:376 / 382
页数:7
相关论文
共 50 条
  • [21] The Use of Health State Utility Values in Decision Models
    Ara, Roberta
    Brazier, John
    Zouraq, Ismail Azzabi
    PHARMACOECONOMICS, 2017, 35 : S77 - S88
  • [22] DISCREPANCY OF HEALTH STATE UTILITY VALUES IN COST-UTILITY ANALYSES OF INTERVENTIONS AGAINST INFECTIOUS DISEASES IN OLDER ADULTS
    Pham, T. H.
    Mihajlovic, J.
    Loncar, I
    Zeevat, F.
    Dagne, A. W.
    Meszaros, K.
    van der Schans, J.
    VALUE IN HEALTH, 2023, 26 (12) : S543 - S543
  • [23] Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis
    Ganz, Michael L.
    Hansen, Brian Bekker
    Valencia, Xavier
    Strandberg-Larsen, Martin
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (05) : 366 - 375
  • [24] Reviewing the literature of cost-effectiveness and cost-utility analysis in health
    Sancho, Leyla Gomes
    CADERNOS DE SAUDE PUBLICA, 2008, 24 (12): : 2735 - 2746
  • [25] A MISSING DATA THRESHOLD AS APPLIED TO HEALTH OUTCOMES DATA: DIFFERENTIAL IMPLICATIONS FOR COST-UTILITY ANALYSIS BY DIAGNOSIS
    Bush, S.
    VALUE IN HEALTH, 2008, 11 (06) : A560 - A560
  • [26] Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in ChildrenTheoretical and Methodological Considerations
    Lisa A. Prosser
    James K. Hammitt
    Ron Keren
    PharmacoEconomics, 2007, 25 : 713 - 726
  • [27] Cost-utility analysis in depression: The McSad utility measure for depression health states
    Bennett, KJ
    Torrance, GW
    Boyle, MH
    Guscott, R
    PSYCHIATRIC SERVICES, 2000, 51 (09) : 1171 - 1176
  • [28] 25 years of cost-utility analyses: State of the field.
    Olchanski, NV
    Rosen, AB
    Chapman, R
    Greenberg, D
    Stone, PW
    Nadai, J
    Neumann, PJ
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 165 - 165
  • [29] Critical appraisal of health-state utility values used in breast cancer-related cost-utility analyses
    Nerich, Virginie
    Saing, Sopany
    Gamper, Eva-Maria
    Holzner, Bernhard
    Pivot, Xavier
    Viney, Rosalie
    Kemmler, Georg
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (03) : 527 - 536
  • [30] An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis
    Rachael Maree Hunter
    Gianluca Baio
    Thomas Butt
    Stephen Morris
    Jeff Round
    Nick Freemantle
    PharmacoEconomics, 2015, 33 : 355 - 366